Skip to content

Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication

Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02246361
Acronym
EDIFIP
Enrollment
211
Registered
2014-09-22
Start date
2014-09-30
Completion date
2015-05-31
Last updated
2015-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankle Sprain, Diverticulitis, Infectious Colitis, Pneumonitis, Prostatitis, Pyelonephritis

Keywords

Ankle sprain, Infectious colitis, Diverticulitis, Pyelonephritis, Prostatitis, Pneumonitis, Patient Information Leaflet (PIL), Doctor Patient Communication, Adherence, Satisfaction, Scale, Doctor Patient Communication scale, Adherence scale, Satisfaction scale

Brief summary

The purpose of this before-after prospective multicenter study is to assess the impact of six Patient Information Leaflets (PILs) on Doctor Patient Communication scale (DPC) and adherence scale for common acute illnesses in emergency ward.

Detailed description

Assessing the impact of six Patient Information Leaflets (PILs) on Doctor Patient Communication scale (DPC) and adherence scale for common acute illnesses (infectious colitis, diverticulitis, pneumonitis, prostatitis, pyelonephritis , ankle sprain) in two emergency ward. For before study without intervention : usual consultation without PIL . For after study with intervention : the patient is given a PIL related to his disease during the consultation. Data collection will take place the same day as the consultation by self-administered questionnaire for DPC scale and also between 7 to 10 days after the consultation by phone survey for DPC scale and adherence scale.

Interventions

PROCEDUREPatient Information Leaflet (PIL)

Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation

Sponsors

Groupe Hospitalier Mutualiste de Grenoble
CollaboratorOTHER
Floralis
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient. * Minor aged over 15 years accompanied by a responsible adult. * The patient must be reachable by telephone within seven to ten days following the consultation.

Exclusion criteria

* Illiterate patient. * Patient refusing follow-up call. * Patient with visual or hearing impairment. * Patient non-Francophone. * Private patient of liberty by judicial or administrative. * Person being a measure of legal protection.

Design outcomes

Primary

MeasureTime frameDescription
Doctor Patient Communication scoreIn seven to ten days after deliveryAll patients will be called seven to ten days after the delivery of a PIL during the visit to answer a questionnaire on their perception of Doctor Patient Communication (DPC) since they visit the GP. Il will permit to calculate a DPC score.

Secondary

MeasureTime frameDescription
Adherence scoreIn seven to ten days after the deliveryAll patients will be called seven to ten days after the delivery of a PIL during the visit, to answer a questionnaire on their adherence related to the disease since they visit the GP. Il will permit to calculate a adherence score.
Satisfaction scoreIn seven to ten days after the deliveryAll patients will be called seven to ten days after the visit, to answer a questionnaire on their satisfaction about since they visit the GP. Il will permit to calculate a satisfaction score.
Doctor Patient Communication scoreJust after the visitAll patients will answer to a self questionnaire on their perception of Doctor Patient Communication (DPC) just after the visit of the GP. Il will permit to calculate a DPC score.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026